These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 8462205)
1. Clinical experience with a new antithrombotic (dermatan sulfate) in chronic hemodialysis patients. Nurmohamed MT; Knipscheer HC; Stevens P; Krediet RT; Roggekamp MC; Berckmans RJ; ten Cate JW Clin Nephrol; 1993 Mar; 39(3):166-71. PubMed ID: 8462205 [TBL] [Abstract][Full Text] [Related]
2. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403 [TBL] [Abstract][Full Text] [Related]
3. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit. Carrie D; Caranobe C; Gabaig AM; Larroche M; Boneu B Thromb Haemost; 1992 Dec; 68(6):637-41. PubMed ID: 1287877 [TBL] [Abstract][Full Text] [Related]
4. The influence of dialyzer geometry on blood coagulation and biocompatibility. Lins LE; Boberg U; Jacobson SH; Kjellstrand C; Ljungberg B; Skröder R Clin Nephrol; 1993 Nov; 40(5):281-5. PubMed ID: 8281717 [TBL] [Abstract][Full Text] [Related]
5. Dermatan sulfate: an alternative to unfractionated heparin for anticoagulation in hemodialysis patients. Vitale C; Berutti S; Bagnis C; Soragna G; Gabella P; Fruttero C; Marangella M J Nephrol; 2013; 26(1):158-63. PubMed ID: 22419236 [TBL] [Abstract][Full Text] [Related]
6. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Chanard J; Lavaud S; Maheut H; Kazes I; Vitry F; Rieu P Nephrol Dial Transplant; 2008 Jun; 23(6):2003-9. PubMed ID: 18156457 [TBL] [Abstract][Full Text] [Related]
7. Effects of dermatan sulfate for anticoagulation in continuous renal replacement therapy. Vitale C; Verdecchia C; Bagnis C; Ganzaroli M; Giorcelli G; Marangella M J Nephrol; 2008; 21(2):205-12. PubMed ID: 18446715 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives. Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702 [TBL] [Abstract][Full Text] [Related]
9. A survey of the clinical experience with dermatan sulfate. Gianese F; Lucchelli PE Semin Thromb Hemost; 1991; 17 Suppl 2():199-204. PubMed ID: 1948090 [No Abstract] [Full Text] [Related]
10. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin. Thomas DP; Gray E; Merton RE Thromb Haemost; 1990 Oct; 64(2):290-3. PubMed ID: 2270536 [TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin. Nurmohamed MT; ten Cate J; Stevens P; Hoek JA; Lins RL; ten Cate JW ASAIO Trans; 1991; 37(3):M459-61. PubMed ID: 1661121 [TBL] [Abstract][Full Text] [Related]
12. Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure. Boccardo P; Melacini D; Rota S; Mecca G; Boletta A; Casiraghi F; Gianese F Nephrol Dial Transplant; 1997 Nov; 12(11):2349-54. PubMed ID: 9394322 [TBL] [Abstract][Full Text] [Related]
13. [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin]. Vukusich A; Avalos C; Orellana G; Cifuentes C; Rivas J; Calderón F Rev Med Chil; 1995 Jun; 123(6):735-41. PubMed ID: 8525227 [TBL] [Abstract][Full Text] [Related]
15. [Use of fragmin in program hemodialysis of patients with terminal chronic renal failure]. Kozlova TV; Shilo VIu; Denisov AIu Klin Med (Mosk); 2005; 83(9):45-9. PubMed ID: 16279040 [TBL] [Abstract][Full Text] [Related]
16. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients. Low CL; Bailie G; Morgan S; Eisele G Clin Nephrol; 1996 Feb; 45(2):120-4. PubMed ID: 8846524 [TBL] [Abstract][Full Text] [Related]
17. [Anticoagulation in hemodialysis sessions with a low molecular weight heparin (CY 222, Choay). Dosage studies in chronic hemodialysis. Its use in patients at high risk of hemorrhage]. Dieval J; Morinière P; Roussel B; Bayrou B; Fournier A; Delobel J J Mal Vasc; 1987; 12 Suppl B():114-8. PubMed ID: 2834482 [TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel dermatan sulfate with high antithrombin activity from ray skin (Raja radula). Ben Mansour M; Dhahri M; Bertholon I; Ollivier V; Bataille I; Ajzenberg N; Hassine M; Jandrot-Perrus M; Chaubet F; Maaroufi RM Thromb Res; 2009 Apr; 123(6):887-94. PubMed ID: 19019412 [TBL] [Abstract][Full Text] [Related]
19. [Use of the low-molecular heparin, Fraxiparine, during hemodialysis]. Monhart V; Petrů K Cas Lek Cesk; 1998 Jan; 137(1):18-21. PubMed ID: 9511272 [TBL] [Abstract][Full Text] [Related]
20. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis. van Wyk V; Badenhorst PN; Kotzé HF Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]